1

Credit Suisse 16th Annual Chemical ConferenceSeptember 26, 2007

2

Forward Looking Statements, Reconciliation and Use of Non-GAAP Measures to U.S. GAAP

Forward-Looking Statements This presentation may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this presentation. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Certain of these risk factors are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Reconciliation of Non-U.S. GAAP Measures to U.S. GAAP This presentation reflects three performance measures, operating EBITDA, adjusted earnings per share, and net debt as non-U.S. GAAP measures. The most directly comparable financial measure presented in accordance with U.S. GAAP in our consolidated financial statements for operating EBITDA is operating profit; for adjusted earnings per share is earnings per common share-diluted; and for net debt is total debt.

Use of Non-U.S. GAAP Financial Information

§ Operating EBITDA, a measure used by management to measure performance, is defined as operating profit from continuing operations, plus equity in net earnings from affiliates, other income and depreciation and amortization, and further adjusted for other charges and adjustments. Our management believes operating EBITDA is useful to investors because it is one of the primary measures our management uses for its planning and budgeting processes and to monitor and evaluate financial and operating results. Operating EBITDA is not a recognized term under U.S. GAAP and does not purport to be an alternative to operating profit as a measure of operating performance or to cash flows from operating activities as a measure of liquidity. Because not all companies use identical calculations, this presentation of operating EBITDA may not be comparable to other similarly titled measures of other companies. Additionally, operating EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements nor does it represent the amount used in our debt covenants.

§ Adjusted earnings per share is a measure used by management to measure performance. It is defined as net earnings (loss) available to

common shareholders plus preferred dividends, adjusted for other charges and adjustments, and divided by the number of basic common shares, diluted preferred shares, and options valued using the treasury method. We provide guidance on an adjusted earnings per share basis and are unable to reconcile forecasted adjusted earnings per share to a GAAP financial measure because a forecast of Other Items is not practical. We believe that the presentation of this non-U.S. GAAP measure provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations, and that when U.S. GAAP information is viewed in conjunction with non-U.S. GAAP information, investors are provided with a more meaningful understanding of our ongoing operating performance. This non-U.S. GAAP information is not intended to be considered in isolation or as a substitute for U.S. GAAP financial information.

§ Net debt is defined as total debt less cash and cash equivalents. We believe that the presentation of this non-U.S. GAAP measure

provides useful information to management and investors regarding changes to the company’s capital structure. Our management and credit analysts use net debt to evaluate the company's capital structure and assess credit quality. This non-U.S. GAAP information is not intended to be considered in isolation or as a substitute for U.S. GAAP financial information.

3

An Attractive Hybrid Business Model

Balance of intermediate & specialty products* Celanese internal peer group

Commodity Chemicals

Intermediate ProductsOil & Gas Consumer

Products

• Motorola• Toyota• Sherwin-Williams• Siemens

• Dow*• Lyondell• Methanex

• Rohm & Haas*• ICI*

Celanese

Specialty Products

• Dow* • Eastman*• PPG*• FMC*

• Exxon• BP• Shell

1 Includes Other Operating Segment, with Revenue of $257 and $117 and Operating EBITDA of ($111) and ($29), respectively

$1.75$3.00Adjusted EPS

$674$1,244Operating EBITDA1 (in $ millions)

$3,111$6,656Revenue1 (in $ millions)

1H20072006

4

40% 35% 25%

Balanced Global and End Market Positions

Notes:Includes oxo alcohol and polyol derivative divestiture and APL acquisitionEnd use breakdown based on 2006 est. external sales revenue

Other11%

Construction

8%

Paints & Coatings

14%

Automotive

9%

Consumer / MedicalApplications

11%

Filter Media

14%

Consumer and Industrial

Adhesives

4%

Textiles

6%Food and Beverage

5%

Chemical Additives

6%

Paper & Packaging

9%

Performance Industrial Applications

3%

5

Execution…Growth…Value

► Phase I : Execution – 2000 to 2006Execute transformation strategy

► Phase II: Growth – 2007 to 2010 Celanese earnings growth strategy

► Ongoing: Value – Deliver solid financial results and shareholder value

Continue to create value in excess of the peer group

6

Focus and strengthen portfolio…2000 to 2006

Portfolio Strategy► Invest in specialty businesses ► Build strength in differentiated intermediates► Extend the acetyl chain globally► Reduce exposure to non-differentiated, more commodity businesses► Divest non-core business lines

Fuel Cells

($1.8 B)$1.8 B

COCPBI

Emulsions GreeceAcrylatesAPL

Estech JVNylonAcetex

DH Actives TrespaphanVinamul

Emulsion PowdersPolyol derivativesClariant Emulsions

VectranOxo alcoholsAir Products PVOH

DivestituresAcquisitions

1Data from the year in which the transaction occurred

Total Revenue Impact1

7

Enhanced market position; reduced commodity exposure

% Revenue from Products Holding #1 or #2 Position

% Revenue from Specialty Businesses

200612000

55%

36%

40%

31%

33%

5%3

Total Revenue$6.2 B

Total Revenue$4.9 B

1IExcludes results from Oxo alcohol business; includes results from APL acquisition2~95% #1 or #2 with the planned 2007 closure of all Celanese methanol production3Primarily methanol and formaldehyde revenue

Non-differentiated Intermediates

Specialty Products

Differentiated Intermediates

20061,22000

Chemical Products

Ticona

Acetate

Nutrinova

~70%

Chemical Products

Ticona

Acetate

Nutrinova

~95%

8

Significantly improved earnings profile since 2000

1Includes estimates for oxo alcohol and polyol derivative divestiture and APL acquisition – Actual 2006 results were $1,244 millionAll numbers are based on CE estimates

Operating EBITDA Growth1

2000 – 2006 ($MM)

290-300

90-9580-85

130-135 40-45

528

~1,180

Baseline 2000 Volume Margin Increase in Earnings from

Affiliates

Portfolio Optimization

Cost Reduction net

of Inflation

2006 Proforma

9

Execution…Growth…Value

► Phase I : Execution – 2000 to 2006Execute transformation strategy

► Phase II: Growth – 2007 to 2010 Celanese earnings growth strategy

► Ongoing: Value – Deliver solid financial results and shareholder value

Continue to create value in excess of the peer group

10

Acetyl Intermediates

Formaldehyde

Anhydride and esters

VAM

Acetic Acid

Differentiated Intermediates Specialty Products

Raw Materials

Building Block

Realigning the businesses to accelerate growth

Engineered Plastics

Nutrinova

Emulsions

Acetate

Engineered Plastics

Nutrinova

Emulsions

Acetate

Raw Materials

Advanced Engineered Materials –

AEM (Ticona)

Engineered Plastics

Consumer and Industrial

Specialties - CIS

Nutrinova

Emulsions/PVOH

Acetate

11

2007 – 2010: Celanese Earnings Growth Strategy

Celanese 2010 Objective:

$300 - $350 million improvement in EBITDA profile

Asia

Revitalization Organic

Balance Sheet

Innovation►Productivity

improvements more than offset inflation

►SG&A improvements

►Nanjing Complex

►Affiliates

►Consumer and Industrial Specialties

► Ticona – new products and applications

►Acetyls –continued greater than market growth in Acetic Acid and VAM

Operational Excellence

►Recapitalized balance sheet (April 2007)

►Continue to evaluate capital structure opportunities

Business Specific

$300-$350 million EBITDA Growth

12

Asia: Enhancing Celanese’s geographic lead

Note: Revenue breakdown based on Celanese 2006 consolidated net sales (does not include sales from equity and cost investments).

Approximately 50% of earnings from the fastest growing region

2006 Regional Split

Europe

Americas

Asia~30%

Europe

Americas

Asia25%

2010E Regional Split

Europe

Americas

Asia45-55%

Europe

Americas

Asia30-35%

RevenueRevenue

Earnings Earnings

13

Consumer Specialties (CS): Acetate drives earnings growth

1 EBITDA as reported excluding special charges, Restructuring in Operations, Other charges. 2 JV dividends from cost investments

Acetate Revitalization will continue to add incremental EBITDA

$220 -230MM

Acetate Operating EBITDA Impact2004 – 2008E

$50

$100

$150

$200

$250

2004 2005 2006 2007E 2008E

$ M

M

Acetate Seg. EBITDA JV Dividends APL

>100% Earnings Growth

1 2

Acetate Revitalization► Revitalization of North

American and European Businesses

► Expansion of China Joint Ventures

► Integration of Acetate Products Limited (APL)

14

Industrial Specialties (IS): Optimize / revitalize for growth and productivity

Marketplace Interface

Operational Excellence

2007 2008 2009

Focus on Controllables

Focus onInnovation

► Enhance customer focus► Revitalize innovation► Consolidate and streamline R&D

functions► Build on capabilities in NA / Asia

► Capture productivity gains► Consolidate manufacturing footprint (YE2008

completion) / enhance production capabilities► Streamline supply chain► Standardize processes, redesign workflows► Accelerate Six Sigma

> $50MM in incremental EBITDA opportunity by 2010

Maximize Business Performance

0

200

400

600

800

1,000

1,200

PVOH ('99)

Clariant('02)

Vinamul('05)

Acquiredbusiness

base

$M

M

Sales 2006E in MM$

Vertical Integration via Acquisition:$200 MM to $1,050 MM

#1 Global Vinyl Emulsions Producer

15

96 %

4 %

Standard Polymers

High Performance Polymers (HPP)Engineering Thermoplastics (ETP)

Global High Performance Polymer and Engineering Thermoplastics2006E: ~8 MM tons (2006E Growth = 6 %)

ABS, SAN, ASA: 4 %

PE = 34 % PP = 19 %

PET = 5 %

PU = 6 %

PVC = 17 % PS, EPS = 9 %

others = 3 %

Comprising: PA 6 & PA 66, PA 11 and PA 12, PC, POM, PBT, COPE, PET technical, PPE, COC & COP, UHMW-PE, PPS, LCP, High Performance Nylons, PEEK, PEI, PES & PSU, PTFE & other fluoropolymers

Range of Products

Perf

orm

ance

€ 100 / kg€ 10 / kg€ 3 / kg

€ 1 / kg

AEM: Focus on High Performance Polymers and Thermoplastics

16

0

100

200

300

400

500

600

2001 2002 2003 2004 2005 2006

Rev

enu

e ($

MM

)

AEM: Increase penetration in transportation; volume growth / product translation in non-transportation

Advanced Engineered Materialstype of resinsin lbs per vehicle

6

40

18

12

2001

Highest Current

2010E

2006E

Non-TransportationTransportation

AEM Non-Transportation Revenue Growth

53%47%

CAGR: 8%

% Non-Automotive Revenue

17

Acetyl Intermediates: Continue organic growth in excess of the market

60

80

100

120

140

160

180

200

1996 1998 2000 2002 2004 2006 2008E

Acetic Acid VAM GDP

Celanese Acetic Acid and Vinyl Acetate Normalized Growth1996-2008E

Celanese: 5.1% (6.3%2)Market3: 4.6%

► Favorable industry dynamics through 2009

► Historical “market-plus” growth continues

► Commercial production from Nanjing began in Q2 2007

$600 - $700 million increased revenues from the Nanjing complex by 2010

>$500 million from Acetyls

► Translate vinyl-based emulsions success to growing Asian market

11996 – 2008 annual growth 2Including the Acetex acquisition 3Source: Tecnon 4Source: CMAI

Gro

wth

CA

GR

1

Global GDP4: 3.1%

VAM

Acetic Acid

Celanese : 4.4% (5.3%2)Market3: 3.5%

18

Acetyl Intermediates: High utilization rates expected through 2009; unmatched operating cost advantage

1Based on effective capacity at 90% of nameplate (Celanese estimate)Source: Celanese estimates; Available Public Data

CapacityUtilization1(Nov, 2006): 91% 93% 92% 91% 91% 92%

0

2,000

4,000

6,000

8,000

10,000

12,000

2004 2005 2006E 2007E 2008E 2009E

KT

High Cost CapacityLow Cost CapacityDemand

Acetic Acid Supply-Demand Balance2009E Acetic Acid Cost Curve

based on Effective Capacity (kt)

0 2,000 4,000 6,000 8,000 10,000 12,000

By-prod

AO Plus™/Leading Competition

Conventional MeOH /CO

High Cost Supply

Pampa (under review)

Celanese technology

19

Execution…Growth…Value

► Phase I : Execution – 2000 to 2006Execute transformation strategy

► Phase II: Growth – 2007 to 2010 Celanese earnings growth strategy

► Ongoing: Value – Deliver solid financial results and shareholder value

Continue to create value in excess of the peer group

20

Celanese Corporation Financial Highlights

$0.71 $0.84Adjusted EPS

28%28%Effective Tax Rate

172.1174.6Diluted Share Basis

$310

$37--

$103

$152

$1,457

2nd Qtr 2006

$326

$106$265

($117)

$71

$1,556

2nd Qtr 2007

Operating EBITDA

Other Charges/Adjustments

Refinancing and Related Costs

Special Items

GAAP Net Earnings (Loss)

Operating Profit

Net Sales

in millions (except EPS)► Net sales increased 7% from the prior

year● Nanjing startup and improved

pricing partially offset reduced volumes in Chemical Products related to Clear Lake

● Volume increases in Ticona● Inclusion of APL sales in Acetate

Products► Operating profit decreased 53% due

to other expenses related to long-term management compensation and restructuring activities

► GAAP net earnings decreased to a loss on expenses related to the debt refinancing

► Adjusted EPS up 18% to $0.84/share► Operating EBITDA increased 5% to

$326

21

► Strong business fundamentals continue

► Continued volume growth in core business

Performance Products

► Improved earnings continue from revitalization efforts

► Integration of APL acquisition

Acetate Products

► Continue >2x GDP volume growth across transportation and non-transportation end-uses

► Continuing high raw material costs

Ticona

► Clear Lake impact to continue into third quarter – unit restarted early August

► Full production rates at Nanjing acetic acid facility

Chemical Products

2007 Business Outlook

2007 Guidance: Adjusted EPS $2.85 to $3.00

Operating EBITDA$1,180 to $1,220 MMClear Lake Impact($0.15) to ($0.25)

22

Well positioned for continued growth and value creation

$300 – $350 million increased EBITDA profile plus EPS potential by 2010

X

X

X

X

Operational Excellence

X

Balance Sheet

X

X

Organic

> $100MMXAcetyl Intermediates

X

Revitalization

X

X

Asia

> $100MMXConsumer and Industrial Specialties

X

Innovation

Incremental EPS

Celanese Corporate

> $100MMAdvanced Engineered Materials

EBITDA ImpactGroup

Primary Growth Focus

Ope

ratin

g EB

ITD

AEP

S

23

Appendix

24

Second Quarter 2007:► Reduced volumes due to unplanned outage of Clear Lake acetic

acid unit► Successful startup of Nanjing acetic acid unit partially offset volume

loss► Sales increased due to higher pricing, currency and continued

strong demand► Pricing strength could not offset margin impact of lower volumes

and higher raw material costs

$207$977

2nd Qtr 2006

$176 down 15%$1,002 up 3%2nd Qtr 2007

Operating EBITDANet Salesin millions

Chemical Products

25

Second Quarter 2007:► Net sales increase driven by strong volume growth (8%) and

currency effect (4%) ► Strong demand continues for all major products in Europe and Asia► Moderate growth in North American automotive and housing

applications supported by strong growth in other end markets► Volume growth partially offset by higher raw material and energy

costs

Ticona Technical Polymers

$66$230

2nd Qtr 2006

$70 up 6%$257 up 12%2nd Qtr 2007

Operating EBITDANet Salesin millions

26

► Increased revenues attributable to inclusion of APL acquisition in Q2► Continued operating margin improvement with revitalization program► Higher dividends from China ventures contributed to EBITDA improvement

Performance Products

► Continued volume growth in Sunett™ and favorable currency impacts did not fully offset decrease in non-core volumes

► Price reductions in line with company expectations

Acetate Products

$55$176

2nd Qtr 2006

$80 up 45%$235 up 34%2nd Qtr 2007

Operating EBITDANet Salesin millions

$21$48

2nd Qtr 2006

$21 $47 down 2%2nd Qtr 2007

Operating EBITDANet Salesin millions

27

Impact from Recent Strategic Initiatives

Balance Sheet Improvements:

$0.08 - $0.12$0.04 - $0.06$0.04 - $0.06Debt Refinancing

($0.21)($0.13)($0.08)Oxo Alcohol Divestiture

2006

($0.11)($0.07)($0.04)Edmonton Methanol Shut Down

Portfolio Enhancements:

$0.61 - $0.63

$0.77Q4

$0.71 - $0.73

$0.79Q3

$1.32 - $1.36Adjusted EPS (Comparable Basis)

$1.56Adjusted EPS (As Reported)HY06

► Divest non-core business lines● Closed sale of oxo alcohol business in Q1 2007 ● Discontinued methanol production unit in Q2 2007

► Capital structure opportunities● Debt refinancing completed in Q2 2007 (reduced debt by ~$113 MM and lowered interest

expense by ~$10-15MM per quarter)● Share repurchases (retired 2.4 million shares with Dutch auction and 8.5 million shares

with Board authorized plan – impacts not fully realized in EPS for Q2 2007)

28

Share Repurchase Program Impacts

0.50.0Restricted Stock Units

12.012.0Convertible Preferred Stock

5.23.1Stock Option Exercises

174.6

156.9

Q2

174.4

159.3

Q1

Weighted Average Diluted Shares Outstanding

Weighted Average Common Shares Outstanding

(amounts in millions)

► Share repurchase activity● Dutch auction – retired 2.4 million shares for approximately $72 million ● Board authorized plan – retired a total of 8.5 million shares at ~$38.88/share (program

completed as of July 23, 2007)► EPS impacts not fully realized for Q2 2007 based on weighted average calculation

(3.5)July share repurchases

149.2Outstanding at 7/23/07

Actual Common Shares Outstanding

1.3Stock option exercises

152.7Outstanding at 6/30/07

(7.3)Share repurchases through Q2

158.7Outstanding at 12/31/06

29

Project delays continue to allow increasing demand to absorb new supply

Operational in 1Q 2006; expansion in July, 2006

Completed, explosion 3 days later

Start 2005150KTSOPO

Construction not yet begun; Expected mid-2009

Construction not yet begun

Start 2008 500KT BP/Sinopec

Commercial Production in 2Q 2006December 2005Early 2005 300KT BP/FPC

Construction under way; Pending Litigation; Startup expected Mid-2007

No sign of constructionStart 2005 200KT Wujing

Commercial Production in July, 2006

Rumored to have started commissioning

Start 2005150KTFanavaran

Commercial Production mid-2005Operational mid-2005Early 2005150KTBP/Yaraco

Expected Late 2009

Website states Q3 2008

NA

Now commercializing

CE Investor Day 2005 Comments

Expected Mid- 2007; replaces high cost capacity

Late 2006200KTDaqing

Commercial Production in 1Q 2006June 2005200KTLunan

Pending Litigation; Expected mid-2009

Start 2008425KTSipchem

Expected Late 20092009200KTHualu Hengsheng

CE Investor Day 2006 UpdatesOriginal DateCapacityCompany

30

Reg G: Reconciliation of Diluted Adjusted EPSAdjusted Earnings Per Share - Reconciliation of a Non-U.S. GAAP Measure

(in $ millions, except per share data) 2007 2006 2007 2006Earnings (loss) from continuing operations before tax and minority interests (168) 134 3 251 Non-GAAP Adjustments: Other charges and other adjustments 1 115 37 166 61 Refinancing costs 256 - 254 - Adjusted earnings from continuing operations before tax and minority interests 203 171 423 312 Income tax provision on adjusted earnings 2 (57) (48) (118) (87)Minority interests - (1) - (1)Adjusted earnings from continuing operations 146 122 305 224Preferred dividends (3) (2) (5) (5)Adjusted net earnings available to common shareholders 143 120 300 219Add back: Preferred dividends 3 2 5 5Adjusted net earnings for adjusted EPS 146 122 305 224

Diluted shares (millions)Weighted average shares outstanding 156.9 158.6 158.1 158.6Assumed conversion of Preferred Shares 12.0 12.0 12.0 12.0 Assumed conversion of Restricted Stock 0.5 - 0.2 - Assumed conversion of stock options 5.2 1.5 4.2 1.4 Total diluted shares 174.6 172.1 174.5 172.0Adjusted EPS 0.84 0.71 1.75 1.301 See Slide 32 for details2 The adjusted tax rate for the three and six months ended June 30, 2007 is 28% based on the original full year 2007 guidance.

Six Months EndedJune 30,

Three Months EndedJune 30,

31

Reg G: Reconciliation of Net Debt

Net Debt - Reconcilation of a Non-U.S. GAAP MeasureJune 30, December 31,

(in $ millions) 2007 2006Short-term borrowings and current installments of long-term debt - third party and affiliates 187 309Long-term debt 3,198 3,189Total debt 3,385 3,498Less: Cash and cash equivalents 470 791Net Debt 2,915 2,707

32

Reg G: Reconciliation of Other Charges and Other Adjustments

Reconciliation of Other Charges and Other Adjustments

Other Charges:

(in $ millions) 2007 2006 2007 2006Employee termination benefits 25 9 25 11 Plant/office closures - 2 - - Total restructuring 25 11 25 11 Insurance recoveries associated with plumbing cases - (2) - (3)Long-term compensation triggered by Exit Event 74 - 74 - Asset impairments 3 - 3 - Ticona Kelsterbach relocation 3 - 3 - Other - 3 1 4 Total 105 12 106 12

Other Adjustments: 1

(in $ millions) 2007 2006 2007 2006Executive severance & other costs related to Squeeze-Out - 13 1 23 Ethylene Pipeline Exit - - 10 Business Optimization 3 - 5 - Foreign exchange loss related to refinancing transaction 9 - 9 - Discontinued Methanol production 2 (2) 12 31 26Other - - 4 - Total 10 25 60 49

Total other charges and other adjustments 115 37 166 61 1 These items are included in net earnings but not included in other charges.2 Adjusted earnings per share included earnings from its discontinued methanol production which was included in the company's 2007 guidance.

June 30, June 30,

Three Months Ended Six Months Ended

Three Months Ended Six Months Ended

June 30, June 30,

33

Reg G: Reconciliation of Operating EBITDASe

gmen

t Dat

a an

d R

econ

cilia

tion

of O

pera

ting

Prof

it (L

oss)

to O

pera

ting

EBIT

DA

-

a N

on-U

.S. G

AAP

Mea

sure

.

(in $

mill

ions

) 20

0720

0620

0720

06N

et S

ales

Che

mic

al P

rodu

cts

1,00

297

72,

004

1,91

4 T

echn

ical

Pol

ymer

s Ti

cona

257

230

519

461

Ace

tate

Pro

duct

s23

517

645

834

3 P

erfo

rman

ce P

rodu

cts

4748

9297

Oth

er A

ctiv

ities

158

6811

712

9 I

nter

segm

ent e

limin

atio

ns(4

3)(4

2)(7

9)(6

7)To

tal

1,55

61,

457

3,11

12,

877

Ope

ratin

g Pr

ofit

(Los

s) C

hem

ical

Pro

duct

s91

130

239

251

Tec

hnic

al P

olym

ers

Tico

na32

3868

79 A

ceta

te P

rodu

cts

2929

5852

Per

form

ance

Pro

duct

s16

1632

33 O

ther

Act

iviti

es 1

(97)

(61)

(120

)(1

07)

Tota

l71

152

277

308

Equi

ty E

arni

ngs

and

Oth

er In

com

e/(E

xpen

se) 2

Che

mic

al P

rodu

cts

1815

2223

Tec

hnic

al P

olym

ers

Tico

na16

1430

29 A

ceta

te P

rodu

cts

34

21

34

21 P

erfo

rman

ce P

rodu

cts

1

1

1

1

Oth

er A

ctiv

ities

1(2

)(4

)3

(3)

Tota

l67

4790

71

Oth

er C

harg

es a

nd O

ther

Adj

ustm

ents

3

Che

mic

al P

rodu

cts

30

2076

33 T

echn

ical

Pol

ymer

s Ti

cona

5

(2

)5

(4)

Ace

tate

Pro

duct

s8

-

9

-

P

erfo

rman

ce P

rodu

cts

-

-

-

-

Oth

er A

ctiv

ities

172

19

7632

Tota

l11

5

3716

661

Dep

reci

atio

n an

d Am

ortiz

atio

n Ex

pens

e C

hem

ical

Pro

duct

s37

4271

75 T

echn

ical

Pol

ymer

s Ti

cona

1716

3432

Ace

tate

Pro

duct

s9

516

12 P

erfo

rman

ce P

rodu

cts

44

88

Oth

er A

ctiv

ities

16

7

12

12

To

tal

7374

141

139

Ope

ratin

g EB

ITD

A C

hem

ical

Pro

duct

s17

620

740

838

2 T

echn

ical

Pol

ymer

s Ti

cona

7066

137

136

Ace

tate

Pro

duct

s80

5511

785

Per

form

ance

Pro

duct

s21

2141

42 O

ther

Act

iviti

es 1

(21)

(39)

(29)

(66)

Tota

l32

631

067

457

91 O

ther

Act

iviti

es p

rimar

ily in

clud

es c

orpo

rate

sel

ling,

gen

eral

and

adm

inis

trativ

e ex

pens

es

and

the

resu

lts fr

om A

T Pl

astic

s an

d ca

ptiv

e in

sura

nce

com

pani

es.

2 I

nclu

des

equi

ty e

arni

ngs

from

affi

liate

s, d

ivid

ends

from

cos

t inv

estm

ents

and

oth

er in

com

e/(e

xpen

se)

3 E

xclu

des

adju

stm

ents

to m

inor

ity in

tere

st, n

et in

tere

st, t

axes

, dep

reci

atio

n, a

mor

tizat

ion

and

disc

ontin

ued

oper

atio

ns.

Thre

e M

onth

s En

ded

June

30,

Six

Mon

ths

Ende

dJu

ne 3

0,

34

Reg G: Reconciliation of 2000 to 2005 Operating EBITDA

Total Celanese 2000 2001 2002 2003 2004 2005GAAP Operating Profit 78 -470 162 133 130 561Depreciation & Amortization 364 372 300 328 256 286Special charges & other adjustments 27 472 -1 6 340 57Equity earnings 18 12 23 39 37 61Cost dividends 40 41 35 53 38 88EBITDA as shown 528 427 519 559 801 1053

Ticona 2000 2001 2002 2003 2004 2005GAAP Operating Profit 90 -13 23 136 19 60Depreciation & Amortization 69 68 60 63 64 60Special charges & other adjustments -27 -8 8 -97 67 31Equity earnings 14 3 15 31 22 48Cost dividends 2 2 2 2 4 5EBITDA as shown 147 52 108 134 176 204

Performance Products 2000 2001 2002 2003 2004 2005GAAP Operating Profit 31 35 50 -49 29 51Depreciation & Amortization 33 28 7 8 12 13Special charges & other adjustments 6 4 0 106 20 1Equity earnings 0 0 0 0 1 0Cost dividends 0 0 1 1 3 -1EBITDA as shown 69 67 58 66 65 64